These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 19200846)

  • 21. [Study on the safety and immunogenicity of MF59-adjuvanted influenza subunit vaccine in Chinese elderly].
    Li RC; Fang HH; Li YP; Liu YP; Nong Y; Huang GB
    Zhonghua Liu Xing Bing Xue Za Zhi; 2008 Jun; 29(6):548-51. PubMed ID: 19040034
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MF-59 adjuvant influence on the functions of gammadelta T cells in HIV-1+ adults immunized with influenza seasonal vaccine.
    Fenoglio D; Zocchi MR; Parodi A; Durando P; Gabutitp G; Gasparini R; Poggi A
    J Prev Med Hyg; 2011 Sep; 52(3):137-41. PubMed ID: 22010544
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MF59™-adjuvanted seasonal influenza vaccine in young children.
    Puig-Barberà J; Pérez-Vilar S; Díez-Domingo J
    Expert Rev Vaccines; 2011 Nov; 10(11):1519-28. PubMed ID: 22043952
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of vaccination with different combinations of MF59-adjuvanted and nonadjuvanted seasonal and pandemic influenza vaccines against pandemic H1N1 (2009) influenza virus infection in ferrets.
    van den Brand JM; Kreijtz JH; Bodewes R; Stittelaar KJ; van Amerongen G; Kuiken T; Simon J; Fouchier RA; Del Giudice G; Rappuoli R; Rimmelzwaan GF; Osterhaus AD
    J Virol; 2011 Mar; 85(6):2851-8. PubMed ID: 21209108
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Detection of anti-H5 responses in human sera by HI using horse erythrocytes following MF59-adjuvanted influenza A/Duck/Singapore/97 vaccine.
    Stephenson I; Wood JM; Nicholson KG; Charlett A; Zambon MC
    Virus Res; 2004 Jul; 103(1-2):91-5. PubMed ID: 15163495
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy.
    Stephenson I; Bugarini R; Nicholson KG; Podda A; Wood JM; Zambon MC; Katz JM
    J Infect Dis; 2005 Apr; 191(8):1210-5. PubMed ID: 15776364
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effectiveness of MF59-adjuvanted subunit influenza vaccine in preventing hospitalisations for cardiovascular disease, cerebrovascular disease and pneumonia in the elderly.
    Puig-Barberà J; Díez-Domingo J; Varea AB; Chavarri GS; Rodrigo JA; Hoyos SP; Vidal DG
    Vaccine; 2007 Oct; 25(42):7313-21. PubMed ID: 17889411
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MF59-adjuvanted influenza vaccine confers superior immunogenicity in adult subjects (18-60 years of age) with chronic diseases who are at risk of post-influenza complications.
    Baldo V; Baldovin T; Floreani A; Carraro AM; Trivello R;
    Vaccine; 2007 May; 25(20):3955-61. PubMed ID: 17383057
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunogenicity, safety, and cross-reactivity of an inactivated, adjuvanted, prototype pandemic influenza (H5N1) vaccine: a phase II, double-blind, randomized trial.
    Wu J; Fang HH; Chen JT; Zhou JC; Feng ZJ; Li CG; Qiu YZ; Liu Y; Lu M; Liu LY; Dong SS; Gao Q; Zhang XM; Wang N; Yin WD; Dong XP
    Clin Infect Dis; 2009 Apr; 48(8):1087-95. PubMed ID: 19281330
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Heterosubtypic protection conferred by combined vaccination with M2e peptide and split influenza vaccine.
    Wu F; Yuan XY; Huang WS; Chen YH
    Vaccine; 2009 Oct; 27(43):6095-101. PubMed ID: 19056447
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile.
    Podda A; Del Giudice G
    Expert Rev Vaccines; 2003 Apr; 2(2):197-203. PubMed ID: 12899571
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacoeconomic evaluation of the MF59--adjuvanted influenza vaccine in the elderly population in Italy.
    Iannazzo S
    J Prev Med Hyg; 2011 Mar; 52(1):1-8. PubMed ID: 21710816
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and effectiveness of MF-59 adjuvanted influenza vaccines in children and adults.
    Black S
    Vaccine; 2015 Jun; 33 Suppl 2():B3-5. PubMed ID: 26022564
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MF59 adjuvant: the best insurance against influenza strain diversity.
    O'Hagan DT; Rappuoli R; De Gregorio E; Tsai T; Del Giudice G
    Expert Rev Vaccines; 2011 Apr; 10(4):447-62. PubMed ID: 21506643
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The comparative effectiveness of adjuvanted and unadjuvanted trivalent inactivated influenza vaccine (TIV) in the elderly.
    Van Buynder PG; Konrad S; Van Buynder JL; Brodkin E; Krajden M; Ramler G; Bigham M
    Vaccine; 2013 Dec; 31(51):6122-8. PubMed ID: 23933368
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Matrix-M™ adjuvation broadens protection induced by seasonal trivalent virosomal influenza vaccine.
    Cox F; Saeland E; Baart M; Koldijk M; Tolboom J; Dekking L; Koudstaal W; Lövgren Bengtsson K; Goudsmit J; Radošević K
    Virol J; 2015 Dec; 12():210. PubMed ID: 26643820
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety of MF59-adjuvanted versus non-adjuvanted influenza vaccines in children and adolescents: an integrated analysis.
    Black S; Della Cioppa G; Malfroot A; Nacci P; Nicolay U; Pellegrini M; Sokal E; Vertruyen A
    Vaccine; 2010 Oct; 28(45):7331-6. PubMed ID: 20813217
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The virosomal adjuvanted influenza vaccine.
    Calcagnile S; Zuccotti GV
    Expert Opin Biol Ther; 2010 Feb; 10(2):191-200. PubMed ID: 20088714
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunogenicity and safety of low dose virosomal adjuvanted influenza vaccine administered intradermally compared to intramuscular full dose administration.
    Künzi V; Klap JM; Seiberling MK; Herzog C; Hartmann K; Kürsteiner O; Kompier R; Grimaldi R; Goudsmit J
    Vaccine; 2009 Jun; 27(27):3561-7. PubMed ID: 19464535
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adjuvants and alternative routes of administration towards the development of the ideal influenza vaccine.
    Durando P; Iudici R; Alicino C; Alberti M; de Florentis D; Ansaldi F; Icardi G
    Hum Vaccin; 2011; 7 Suppl():29-40. PubMed ID: 21245655
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.